Nucleus

Trending topics and news in HCT and Cellular Therapy

Topics to Explore

Topics to Explore

Science Highlights

Exploring Cost-effectiveness in Transplantation and Cellular Therapies: Insights from Dr. Amar Kelkar at the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

by Dr. Andrés Gómez De León, MD

Dr. Amar Kelkar from Dana Farber Cancer Institute presented concepts that should be in the minds of all...

ASTCT News

Beyond BCMA: Exploring Talquetamab in Myeloma Therapy

by ASTCT Talks

In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Amrita Krishnan, MD. They delve into the use of GPRC5D as a target in myeloma therapy, specifically focusing...

GVHD

Pre-HCT gut microbiota diversity and outcomes in children

by ASTCT Science Highlights

Masetti R, Leardini D, Muratore E, et al. Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as Predictor of Mortality in Children. Blood. 2023; (doi:...

Science Highlights

Motixafortide + G-CSF boosts CD34+ HSPCs in MM patients for ASCT

by ASTCT Science Highlights

A single injection of motixafortide + granulocyte colony-stimulating factor (G-CSF) in multiple myeloma (MM) patients undergoing autologous stem cell transplantation mobilized more CD34+...

Bispecifics

Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL

by Eleanor Mayfield, ELS

Blinatumomab added to the Interfant-06 chemotherapy regimen appeared safe and was highly efficacious in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia (ALL) compared...

Science Highlights

Combining TIGIT inhibition with immunomodulary drugs may prevent MM progression after SCT

by ASTCT Science Highlights

Minnie SA, Waltner OG, Ensbey KS, et al. TIGIT Inhibition and Lenalidomide Synergistically Promote Anti-Myeloma Immune Responses After Stem Cell Transplantation in Mice. Journal of Clinical...

RELATED NEWS

CAR T

PTGFRN CAR-T cell therapy studied as a potential therapeutic target for glioblastoma

by Cancer Immunology, Immunotherapy

Scientists believe prostaglandin F2 receptor negative regulator (PTGFRN) is a possible target for chimeric antigen receptor (CAR) T-cell therapy in patients with glioblastoma (GBM).

CAR T

Insulating HSPCs from autologous CAR33-directed CAR T cells

by Blood Advances

Researchers report the safety of a novel approach to insulate edited cells from chimeric antigen receptor (CAR) selection and attack.